mRNA Vaccine Targeting Epstein-Barr Virus (EBV) in Healthy Young Adults

Starting soon · Phase 1 · Has a placebo group

Conditions studied: EBV

In brief

This is an adaptive design Phase 1 clinical trial to evaluate the safety and immunogenicity of VXCO-102 in healthy adult participants.

Key facts

Study ID

NCT07557602

Run by

Vaccine Company, Inc.

People needed

45

Starts

2026-05-04

Expected to finish

2027-08-31

Last updated by the study team

2026-04-29

Who can join

Age: 18 and older, up to 25. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Aged 18 to 25 years, inclusive
• Healthy per medical assessment based on self-reported medical history, physical examination, vital signs, and laboratory assessment

You may not qualify if…

• Self-reported or medically-documented significant medical or psychiatric condition that per medical assessment could interfere with study participation
• Likely or confirmed myocarditis or pericarditis
• Prior receipt of an investigational EBV vaccine
• Prior receipt of a licensed vaccine within 56 days prior to Day 1
• Received more than 10 days of any systemic immunosuppressants or cytotoxic medications within 56 days prior to Day 1, any within 14 days prior to Day 1, or will need immunosuppressants at any time during the study.
• For participants of childbearing potential: pregnant, breastfeeding or planning to become pregnant during the study
• Note: Other inclusion and exclusion criteria apply.

Where it is running

• Q-Pharm Pty Ltd/Nucleus Network Pty Ltd — Herston, Queensland, Australia
• Nucleus Network Pty Ltd — Melbourne, Victoria, Australia

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.